Stockscreener 앱 받기
1.53
5.52%
0.08
전일 마감가:
$1.45
열려 있는:
$1.44
하루 거래량:
5.05M
Relative Volume:
4.49
시가총액:
$205.88M
수익:
-
순이익/손실:
$-101.70M
주가수익비율:
-0.8069
EPS:
-1.8961
순현금흐름:
$-84.35M
1주 성능:
+0.66%
1개월 성능:
-23.50%
6개월 성능:
+8.51%
1년 성능:
+214.49%
1일 변동 폭
$1.405
$1.545
1주일 범위
$1.37
$1.61
52주 변동 폭
$0.404
$2.66
AIx 온콜로지 Stock (ALXO) Company Profile
명칭
Alx Oncology Holdings Inc
전화
650-466-7125
주소
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.53 | 205.88M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIx 온콜로지 Stock (ALXO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-19 | 개시 | Wells Fargo | Overweight |
| 2026-03-06 | 재개 | UBS | Buy |
| 2025-11-13 | 개시 | Jefferies | Buy |
| 2025-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-06 | 개시 | UBS | Buy |
| 2021-02-10 | 개시 | H.C. Wainwright | Buy |
| 2020-08-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 개시 | Credit Suisse | Outperform |
| 2020-08-11 | 개시 | Jefferies | Buy |
| 2020-08-11 | 개시 | Piper Sandler | Overweight |
모두보기
AIx 온콜로지 주식(ALXO)의 최신 뉴스
ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALX Oncology Holdings Inc (ALXO) Valuation: PE, PB & Fair Value Analysis - TradingKey
ALX Oncology Holdings Inc (ALXO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ALX Oncology Holdings Inc (ALXO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ALX Oncology Holdings Inc (ALXO) Institutional Confidence - TradingKey
ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALX Oncology Holdings Inc (ALXO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ALX Oncology Holdings Inc (ALXO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ALXO Q1 2026 Earnings: EPS Beat Amid Pre‑Revenue Development StageMargin Guidance - newsline.com
ALX Oncology (ALXO) Edges Higher: Near-Term Support and Resistance in FocusLow Volume Node - newsline.com
ALXO Q1 2026 Earnings: EPS Surprise of 26.23% Highlights Cost Discipline Amid Clinical ProgressRevenue Recognition Risk - newsline.com
ALXO Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Shares HigherEarnings Cycle Outlook - newsline.com
ALXO News | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALX Oncology Shareholders Approve Directors and Executive Pay - TipRanks
ALX Oncology (NASDAQ: ALXO) holders back board slate, executive pay and KPMG audit - Stock Titan
ALX Oncology targets key readouts to advance CD47, EGFR cancer drug programs - MSN
ALXO: All voting proposals passed and clinical programs advanced, with key data expected soon - TradingView
ALX Oncology Holdings Inc Annual Shareholders Meeting Transcript - GuruFocus
ALXO Q1 2026 Earnings: EPS Beat Highlights Improved Cost Control in Pre-Revenue StageManagement Tone Analysis - newsline.com
ALXO Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Disciplined Cost ManagementFinancial Health Score - newsline.com
ALX Oncology (ALXO) Q1 2026 Earnings Transcript - AOL.com
ALXO Q1 2026 Earnings: EPS Beat Driven by Lower Expenses, Stock Slightly DownProfit Cycle Analysis - newsline.com
Insider Returns Down To US$122k As ALX Oncology Holdings' Stock Dips 15% - simplywall.st
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs - inkl
ALXO: Evorpacept and ALX2004 advance with strong data, robust funding, and pivotal trials planned - TradingView
ALXO: Evorpacept and ALX2004 advance with strong data, targeting high unmet needs and pivotal trials ahead - TradingView
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York - Investing News Network
Cancer-therapy biotech ALX Oncology to join Jefferies 2026 - Stock Titan
ALXO Stock Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALX Oncology Slips 1.5% as Biotech Stock Tests Key Support at $1.83Fibonacci Entry Signals - newsline.com
ALXO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Evorpacept DevelopmentEPS Revision Trend - The Legal Advocate
ALX Oncology Holdings (ALXO) Holds Steady Near Support as Biotech Sector Watches Catalyst CalendarTrend Reversal Picks - newsline.com
Is ALX Oncology Holdings (ALXO) outperforming other medical stocks this year? - MSN
ALX Oncology (ALXO) Edges Higher Amid Modest Buying Interest; Resistance at $2.06 in FocusMoney Flow Index - The Legal Advocate
ALX Oncology (ALXO) Lightstone group falls below 5% ownership - Stock Titan
ALXO Q1 2026 Earnings: Narrower-than-Expected Loss per Share Mirrors Clinical-Stage FocusEarnings Season Outlook - newsline.com
ALXO Q1 2026 Earnings: EPS Beat Highlights Controlled Cash Burn, No Revenue YetDividend Cut Risk - Newser
Why Is ALX Oncology Holdings Inc. (ALXO) Stock Down Today? - Meyka
ALXO Stock Price, Quote & Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
Redmile Group, ALXO: Investment manager discloses 6.8% ownership - Stock Titan
HBM Healthcare (ALXO) discloses 8.59M shares, ~6.5% stake - Stock Titan
Earnings call transcript: ALX Oncology beats Q1 2026 earnings forecast - Investing.com
Q2 EPS Estimates for ALX Oncology Raised by HC Wainwright - MarketBeat
TradingKey - TradingKey
UBS Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q1 2026 Earnings Call Transcript - Insider Monkey
Alx Oncology Signals Promise, But Validation Looms - TipRanks
ALX Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS - MSN
AIx 온콜로지 (ALXO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):